
www.chemmedchem.org

CHEMMEDCHEM

CHEMISTRY ENABLING DRUG DISCOVERY



ISMC 2012
Book of Abstracts





P034

Ganoderma lucidum Methanolic Extract: Chemical Characterization in Phenolic Compounds and Study of Growth Inhibitory Activity in Iluman Tumour Cell Lines

Sandrina A. Heleno, Itali Catarina Tavares, Ici Josiana A. Vaz, Ical Gabriela M. Almeida, Ici Anabela Martins, I^{ci} Marla João R.P. Quelroz, I^{ci} M. Helena Vasconcelos, Ical Isabel C.F.R. Ferreira I^{ci}

[a] CIMO-Instituto Politécnico de Bragança Compus de Santa Apolônia, Apartodo 1172, 5301-855 Bragança, Portugal [h] Centro de Químira, Universidade do Minho, Campus de Gualtar 4710-057 Braga, Portugal (c] IPATIMUP - Institute of Moleculus Pathology and Immunology of the University of Porto, Portugal [d] Department of Biological Sciences, Poculty of Pharmacy, University of Porto, Portugal

Ganoderma lucidum is one of the most extensively studied mushroom species due to its medicinal properties. It has been used as functional food and as chemopreventer in some countries for thousands of years, and became apopular dietary supplementing redient in Western countries.[1] Some of its pharmacological properties have been related to antitumour properties, attributed to a wide variety of bioactive components such as polysaccharides, triterpenes, sterols, fectins and some proteins.[2,3] Nevertheless, the bioactive properties of its phenolic compounds have not been studied. The aim of this work was to study the potential antitumor activity of the methanolic extract of this mushroom. This extract of Ganoderma lucidum, collected in Northeast Portugal, was characterized in phenolic compounds by high performance liquid chromatography coupled to photodiode array detection and mass spectrometry (HPLC-DAD-MS). The extract was further submitted to evaluation of growth inhibitory activity in four human tumour cell lines (MCF-7, NCI-H460, HCT15 and AGS), by the sulforhodamine B assay.

The extract presented a moderate growth inhibitory activity in all the cell lines tested (GI_{ss} =93.3 \pm 18.1–112.6 \pm 11.7 $\mu g/mL$).The following compounds were identified in the extract: ρ -hydroxybenzoic acid (0.58 \pm 0.04 mg/100 g dw), ρ -coumaricacid (0.38 \pm 0.03 mg/100 g dw) and cinnamic acid (0.28 \pm 0.03 mg/100 g dw). Future work will excludate the mechanism of action of the studied extract leading to the observed cell growth Inhibition.

Acknowledgements: Funding from the FCT and FEDER COMPETE/ CREN/EU through project PTDC/AGR-ALI/110062/2009 and through the research centres (PFst-C/QII/UII0686/2011 and PFst-OF/AGR/ UI0690/2011) is acknowledged. S. A. Heleno also thanks the FCT for a PhD grant (SFRH/8D/70304/2010).

References

R. Sullivan, J. E. Smith, N. J. Rowan, Perspect. Biol. Med. 2006, 49, 159–170.
 R. R. M. Paterson, Phytochemistry 2006, 67, 1985–2001.

[3] I. C. F. R. Ferreira, J. A. Vaz, M. H. Vasconcelos, A. Martins, Anti-Cancer Agents Med. Chem. 2010, 10, 424–436.

P035

Indication of Brain Penetrable Compounds in Plant Extracts by PAMPA-BBB-LC-MS Assay

<u>György T. Balogh, [a]</u> Árpád Könczöl, [d] Judit Müller, [ab] Emília Földes, [b] Engel Rita, [d] Zoltán Béni, [d] Ágnes Kéry^[a]

[a] Compound Profiling Laboratory, Gedeon Richter Pic., Budapest, Hungary
[b] Department of Organic Chemistry and Technology, Budapest University
of Technology and Economics, Budapest, Hungary
[c] Institute of Ecology and Botanr, Centre for Ecological Research of the
Hungarian Academy of Sciences, Vacrátát, Hungary
[d] Spectroscopic Research, Gedeon Richter Pic, Budapest, Hungary
[a] Department of Phermacognesy, Semmelwer University,
Eudapest, Hungary email: y. belogh@gmail.com

Plant extracts with proven neurological bioactivity are attractive and potential targets for central nervous system (CNS) drug discovery. In the vast majority of cases, however, the molecular mechanism of action and the constituents responsible for activity remain undear or uncertain due to the complexity of natural products. To overcome this issue, predicting and evaluating the blood-brain barrier (EBB) permeability of natural products is of key importance. Parallel artificial membrane permeability assay (FAMFA) is a robust, 96-well plate assay-based in vitro method for assessing the rate of transcellular passive permeability of drug candidates through the BBB. The goal of our study was to validate the applicability of the PAMPA-BBB assay coupled with LC-MS for identifying brain penetrable compounds in really complex mixtures. Our validation set contained 43 natural product drugs and natural product-like drugs with experimental blood-brain partition coefficients (logBB=log(C_{look}/C_{blood})) ranging evenly from -2.0 to 1.0 in value. In order to measure the effective permeability (P_{*}) and membrane retention (MR%) of each test compound, rapid LC MS methods were developed. Finally, we dem onstrate the applicability and advantages of PAMPA-BBB assay with the extract of Corydalis cava and Tanacetum parthenium, containing several CNS active benzylisoguinoline alkaloids and sesquiterpene lactones, respectively.